Furthermore, Xcel Peptides offers researchers a BPC-157 + TB-500 blend and stable BPC-157 capsules
The Exendin-4 story has been pivotal for supporting the idea that other peptides from venoms can be considered for developing antidiabetic medicines
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
Compounded GLP-1s have not been evaluated by the FDA, but side effects are expected to be similar to other GLP-1-based medications reviewed by the FDA, which have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar), flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder)